Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2935

1.

OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.

Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M.

Gynecol Oncol. 2019 Aug 12. pii: S0090-8258(19)31460-X. doi: 10.1016/j.ygyno.2019.08.009. [Epub ahead of print]

PMID:
31416612
2.

The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.

Lheureux S, Mirza M, Coleman R.

J Clin Oncol. 2019 Aug 12:JCO1900347. doi: 10.1200/JCO.19.00347. [Epub ahead of print] No abstract available.

PMID:
31403862
3.

Left Atrial Decompression on Venoarterial Extracorporeal Membrane Oxygenation: Getting to the Heart of the Matter.

Coleman RD, Chartan CA, Qureshi AM, Shekerdemian LS.

Pediatr Crit Care Med. 2019 Aug;20(8):780-781. doi: 10.1097/PCC.0000000000001956. No abstract available.

PMID:
31397811
4.

Salmonella from a Microtidal Estuary Are Capable of Invading Human Intestinal Cell Lines.

Siddiqee MH, Henry R, Deletic A, Bulach DM, Coleman RA, McCarthy DT.

Microb Ecol. 2019 Aug 5. doi: 10.1007/s00248-019-01419-2. [Epub ahead of print]

PMID:
31384980
5.

Individual, social, and environmental factors affecting salivary and fecal cortisol levels in captive pied tamarins (Saguinus bicolor).

Price E, Coleman R, Ahsmann J, Glendewar G, Hunt J, Smith T, Wormell D.

Am J Primatol. 2019 Aug 1:e23033. doi: 10.1002/ajp.23033. [Epub ahead of print]

PMID:
31368125
6.

Using metabolomics to assess the sub-lethal effects of zinc and boscalid on an estuarine polychaete worm over time.

Sinclair GM, O'Brien AL, Keough M, De Souza DP, Dayalan S, Kanojia K, Kouremenos K, Tull DL, Coleman RA, Jones OAH, Long SM.

Metabolomics. 2019 Jul 31;15(8):108. doi: 10.1007/s11306-019-1570-x.

PMID:
31367897
7.

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Chelariu-Raicu A, Coleman RL, Sood AK.

Oncology (Williston Park). 2019 Jul 16;33(7). pii: 629378.

8.

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, Gil da Costa RM, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C.

J Clin Invest. 2019 Jul 30;130. pii: 128212. doi: 10.1172/JCI128212.

9.

Enantiomeric 4'-Truncated 3-deaza-1',6'-isoneplanocins: Synthesis and antiviral properties including Ebola.

Liu C, Coleman R, Archer A, Hussein I, Bowlin TL, Chen Q, Schneller SW.

Bioorg Med Chem Lett. 2019 Jul 11. pii: S0960-894X(19)30465-2. doi: 10.1016/j.bmcl.2019.07.021. [Epub ahead of print]

PMID:
31358469
10.

Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK.

Gynecol Oncol. 2019 Jul 25. pii: S0090-8258(19)31353-8. doi: 10.1016/j.ygyno.2019.07.004. [Epub ahead of print]

PMID:
31353053
11.

Brief report: Department of Defense midseason estimates of vaccine effectiveness for the 2018-2019 influenza season.

Lynch LC, Coleman R, DeMarcus L, Scheckelhoff M, Eick-Cost AA, Hu Z, Hansen CJ, Graf PCF, Myers CA, Federinko S, Johnson A.

MSMR. 2019 Jul;26(7):24-27. No abstract available.

12.

Perturbation of the interactions of calmodulin with GRK5 using a natural product chemical probe.

Beyett TS, Fraley AE, Labudde E, Patra D, Coleman RC, Eguchi A, Glukhova A, Chen Q, Williams RM, Koch WJ, Sherman DH, Tesmer JJG.

Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15895-15900. doi: 10.1073/pnas.1818547116. Epub 2019 Jul 23.

PMID:
31337679
13.

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc.

Gynecol Oncol. 2019 Aug;154(2):255-258. doi: 10.1016/j.ygyno.2019.04.677. No abstract available.

PMID:
31331494
14.

Joint ENGOT and GOG Foundation requirements for trials with industry partners.

Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc.

Int J Gynecol Cancer. 2019 Jul 18. pii: ijgc-2019-000441. doi: 10.1136/ijgc-2019-000441. [Epub ahead of print] No abstract available.

PMID:
31320391
15.

A di-iron protein recruited as an Fe[II] and oxygen sensor for bacterial chemotaxis functions by stabilizing an iron-peroxy species.

Muok AR, Deng Y, Gumerov VM, Chong JE, DeRosa JR, Kurniyati K, Coleman RE, Lancaster KM, Li C, Zhulin IB, Crane BR.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):14955-14960. doi: 10.1073/pnas.1904234116. Epub 2019 Jul 3.

PMID:
31270241
16.

Methods to Discover and Evaluate Proteasome Small Molecule Stimulators.

Coleman RA, Trader DJ.

Molecules. 2019 Jun 25;24(12). pii: E2341. doi: 10.3390/molecules24122341. Review.

17.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009. [Epub ahead of print]

PMID:
31216226
18.

Oral treprostinil use in children: a multicenter, observational experience.

Kanaan U, Varghese NP, Coleman RD, Huckaby J, Lawrence P, Jorgensen LO, Miller-Reed K, Day RW, Mallory GB, Ivy DD.

Pulm Circ. 2019 Jul-Sep;9(3):2045894019862138. doi: 10.1177/2045894019862138.

19.

Estimation of Actual and Ideal Bodyweight Using Morphometric Measurements of Miniature, Saddle-Type, and Thoroughbred Horses.

Catalano DN, Coleman RJ, Hathaway MR, Neu AE, Wagner EL, Tyler PJ, McCue ME, Martinson KL.

J Equine Vet Sci. 2019 Jul;78:117-122. doi: 10.1016/j.jevs.2019.04.008. Epub 2019 May 13.

PMID:
31203974
20.

The effect of articular cartilage focal defect size and location in whole knee biomechanics models.

Marchi BC, Arruda EM, Coleman R.

J Biomech Eng. 2019 Jun 15. doi: 10.1115/1.4044032. [Epub ahead of print]

PMID:
31201745
21.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

22.

Understanding spatiotemporal variability of in-stream water quality in urban environments - A case study of Melbourne, Australia.

Shi B, Bach PM, Lintern A, Zhang K, Coleman RA, Metzeling L, McCarthy DT, Deletic A.

J Environ Manage. 2019 Sep 15;246:203-213. doi: 10.1016/j.jenvman.2019.06.006. Epub 2019 Jun 6.

PMID:
31176982
23.

The plus maze and scototaxis test are not valid behavioral assays for anxiety assessment in the South African clawed frog.

Coleman RB, Aguirre K, Spiegel HP, Pecos C, Carr JA, Harris BN.

J Comp Physiol A Neuroethol Sens Neural Behav Physiol. 2019 Aug;205(4):567-582. doi: 10.1007/s00359-019-01351-3. Epub 2019 May 29.

PMID:
31144017
24.

Equine Fecal Microbiota Changes Associated With Anthelmintic Administration.

Kunz IGZ, Reed KJ, Metcalf JL, Hassel DM, Coleman RJ, Hess TM, Coleman SJ.

J Equine Vet Sci. 2019 Jun;77:98-106. doi: 10.1016/j.jevs.2019.01.018. Epub 2019 Feb 13.

PMID:
31133326
25.

Advancing Drug Development in Gynecologic Malignancies.

Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ.

Clin Cancer Res. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24.

PMID:
31126961
26.

Life-history characteristics of an exploited bonefish Albula glossodonta population in a remote South Pacific atoll.

Filous A, Lennox RJ, Coleman RR, Friedlander AM, Clua EEG, Danylchuk AJ.

J Fish Biol. 2019 Aug;95(2):562-574. doi: 10.1111/jfb.14057. Epub 2019 Jun 27.

PMID:
31119738
27.

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.

Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL.

Int J Gynecol Cancer. 2019 May 22. pii: ijgc-2019-000499. doi: 10.1136/ijgc-2019-000499. [Epub ahead of print]

PMID:
31118216
28.

Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?

Gaillard SL, Coleman RL.

Ann Oncol. 2019 May 21. pii: mdz166. doi: 10.1093/annonc/mdz166. [Epub ahead of print] No abstract available.

PMID:
31111866
29.

Implementing a Central IRB Model in a Multicenter Research Network.

Burr JS, Johnson AR, Vasenina V, Bisping S, Coleman RW, Botkin JR, Dean JM.

Ethics Hum Res. 2019 May;41(3):23-28. doi: 10.1002/eahr.500016.

PMID:
31108575
30.

Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).

Maddaloni E, Coleman RL, Pozzilli P, Holman RR.

Diabetes Obes Metab. 2019 Sep;21(9):2115-2122. doi: 10.1111/dom.13788. Epub 2019 Jun 19.

PMID:
31099472
31.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
32.

Pilot study of a ketogenic diet in relapsing-remitting MS.

Brenton JN, Banwell B, Bergqvist AGC, Lehner-Gulotta D, Gampper L, Leytham E, Coleman R, Goldman MD.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 12;6(4):e565. doi: 10.1212/NXI.0000000000000565. eCollection 2019 Jul.

33.

The endangered White's seahorse Hippocampus whitei chooses artificial over natural habitats.

Simpson M, Morris RL, Harasti D, Coleman RA.

J Fish Biol. 2019 Aug;95(2):555-561. doi: 10.1111/jfb.14002. Epub 2019 May 30.

PMID:
31073989
34.

Department of Defense end-of-season influenza vaccine effectiveness estimates for the 2017-2018 season.

Coleman R, Eick-Cost AA, Hawksworth AW, Hu Z, Lynch L, Myers CA, DeMarcus L, Federinko S.

MSMR. 2018 Oct;25(10):16-20.

PMID:
31066571
35.

Extracorporeal Membrane Oxygenation Mortality in High-Risk Populations: An Analysis of the Pediatric Health Information System Database.

Coleman RD, Goldman J, Moffett B, Guffey D, Loftis L, Thomas J, Shekerdemian LS.

ASAIO J. 2019 Apr 15. doi: 10.1097/MAT.0000000000001002. [Epub ahead of print]

PMID:
31045920
36.

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.

Sestak I, Blake GM, Patel R, Coleman RE, Cuzick J, Eastell R.

Bone. 2019 Jul;124:83-88. doi: 10.1016/j.bone.2019.04.016. Epub 2019 Apr 24.

37.

A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.

Woodward DF, Wang JW, Coleman RA, Woodrooffe AJ, Clark KL, Stamer WD, Tao G, Fan S, Toris CB.

J Ocul Pharmacol Ther. 2019 Jun;35(5):265-277. doi: 10.1089/jop.2018.0126. Epub 2019 Apr 25.

PMID:
31025909
38.

Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.

Falchook G, Coleman RL, Schilder RJ.

JAMA Oncol. 2019 Jun 1;5(6):910-911. doi: 10.1001/jamaoncol.2019.0562. No abstract available.

PMID:
31021370
39.

Public Health Surveillance Studies of Alcohol Industry Market and Political Strategies: A Systematic Review.

McCambridge J, Coleman R, McEachern J.

J Stud Alcohol Drugs. 2019 Mar;80(2):149-157.

PMID:
31014459
40.

Defective fatty acid oxidation in mice with muscle-specific acyl-CoA synthetase 1 deficiency increases amino acid use and impairs muscle function.

Zhao L, Pascual F, Bacudio L, Suchanek AL, Young PA, Li LO, Martin SA, Camporez JP, Perry RJ, Shulman GI, Klett EL, Coleman RA.

J Biol Chem. 2019 May 31;294(22):8819-8833. doi: 10.1074/jbc.RA118.006790. Epub 2019 Apr 11.

PMID:
30975900
41.

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.

D'Oronzo S, Coleman R, Brown J, Silvestris F.

J Bone Oncol. 2018 Nov 6;15:004-4. doi: 10.1016/j.jbo.2018.10.004. eCollection 2019 Apr. Review.

42.

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

PMID:
30926640
43.

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Lin R, Coleman RL, Yuan Y.

J Natl Cancer Inst. 2019 Mar 29. pii: djz049. doi: 10.1093/jnci/djz049. [Epub ahead of print]

PMID:
30924863
44.

Microsatellite instability in endometrial cancer: New purpose for an old test.

Kurnit KC, Westin SN, Coleman RL.

Cancer. 2019 Mar 26. doi: 10.1002/cncr.32058. [Epub ahead of print] No abstract available.

PMID:
30913308
45.

An 11-Month-Old Male With Acute-Onset Left-Sided Facial Paralysis.

Posa M, Nestor K, Coleman R, Rajderkar D, Kelly MN.

Clin Pediatr (Phila). 2019 May;58(5):594-598. doi: 10.1177/0009922819837354. Epub 2019 Mar 22. No abstract available.

PMID:
30897949
46.

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.

Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.

PMID:
30887020
47.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
48.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
49.

Emotional experience in parents of children with Zellweger spectrum disorders: A qualitative study.

Bose M, Mahadevan M, Schules DR, Coleman RK, Gawron KM, Gamble MB, Roullet JB, Gibson KM, Rizzo WB.

Mol Genet Metab Rep. 2019 Feb 14;19:100459. doi: 10.1016/j.ymgmr.2019.100459. eCollection 2019 Jun.

50.

Neutral Lipid Storage Diseases as Cellular Model to Study Lipid Droplet Function.

Missaglia S, Coleman RA, Mordente A, Tavian D.

Cells. 2019 Feb 21;8(2). pii: E187. doi: 10.3390/cells8020187. Review.

Supplemental Content

Loading ...
Support Center